Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Interaction of Axonal Chondrolectin with Collagen XIXa1 Is Necessary for Precise Neuromuscular Junction Formation.

Oprişoreanu AM, Smith HL, Arya S, Webster R, Zhong Z, Wehner D, Cardozo MJ, Becker T, Talbot K, Becker CG.

Cell Rep. 2019 Oct 29;29(5):1082-1098.e10. doi: 10.1016/j.celrep.2019.09.033.

2.

Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo.

Williamson MG, Finelli MJ, Sleigh JN, Reddington A, Gordon D, Talbot K, Davies KE, Oliver PL.

Hum Mol Genet. 2019 Sep 6. pii: ddz190. doi: 10.1093/hmg/ddz190. [Epub ahead of print]

PMID:
31642482
3.

Wrangling RNA: Antisense oligonucleotides for neurological disorders.

Talbot K, Wood MJA.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaay2069. doi: 10.1126/scitranslmed.aay2069. Review.

PMID:
31554737
4.

Tracheostomy in motor neurone disease.

Turner MR, Faull C, McDermott CJ, Nickol AH, Palmer J, Talbot K.

Pract Neurol. 2019 Dec;19(6):467-475. doi: 10.1136/practneurol-2018-002109. Epub 2019 Jul 4. Review.

PMID:
31273080
5.

CSF chitinase proteins in amyotrophic lateral sclerosis.

Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1215-1220. doi: 10.1136/jnnp-2019-320442. Epub 2019 May 23.

PMID:
31123140
6.

The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease.

Young CA, Ealing J, McDermott C, Williams T, Al-Chalabi A, Majeed T, Burke G, Pinto A, Dick D, Talbot K, Harrower T, Walsh J, Chandran S, Hanemann CO, Mills R, Tennant A.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):317-327. doi: 10.1080/21678421.2019.1615951. Epub 2019 May 22.

PMID:
31116037
7.

The sensory and affective components of pain: are they differentially modifiable dimensions or inseparable aspects of a unitary experience? A systematic review.

Talbot K, Madden VJ, Jones SL, Moseley GL.

Br J Anaesth. 2019 Aug;123(2):e263-e272. doi: 10.1016/j.bja.2019.03.033. Epub 2019 May 1.

8.

Influence of Sex and Maximum Strength on Reactive Strength Index-Modified.

Beckham GK, Suchomel TJ, Sole CJ, Bailey CA, Grazer JL, Kim SB, Talbot KB, Stone MH.

J Sports Sci Med. 2019 Feb 11;18(1):65-72. eCollection 2019 Mar.

9.

Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis.

Allen SP, Hall B, Castelli LM, Francis L, Woof R, Siskos AP, Kouloura E, Gray E, Thompson AG, Talbot K, Higginbottom A, Myszczynska M, Allen CF, Stopford MJ, Hemingway J, Bauer CS, Webster CP, De Vos KJ, Turner MR, Keun HC, Hautbergue GM, Ferraiuolo L, Shaw PJ.

Brain. 2019 Mar 1;142(3):586-605. doi: 10.1093/brain/awy353.

10.

Cerebellar tract alterations in PLS and ALS.

Tu S, Menke RAL, Talbot K, Kiernan MC, Turner MR.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):281-284. doi: 10.1080/21678421.2018.1562554. Epub 2019 Jan 21.

PMID:
30663900
11.

UFLC-Derived CSF Extracellular Vesicle Origin and Proteome.

Thompson AG, Gray E, Mager I, Fischer R, Thézénas ML, Charles PD, Talbot K, El Andaloussi S, Kessler BM, Wood M, Turner MR.

Proteomics. 2018 Dec;18(24):e1800257. doi: 10.1002/pmic.201800257. Epub 2018 Dec 10.

PMID:
30411858
12.

Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction.

Gordon D, Dafinca R, Scaber J, Alegre-Abarrategui J, Farrimond L, Scott C, Biggs D, Kent L, Oliver PL, Davies B, Ansorge O, Wade-Martins R, Talbot K.

Neurobiol Dis. 2019 Jan;121:148-162. doi: 10.1016/j.nbd.2018.09.024. Epub 2018 Oct 2.

13.

Neurodegeneration in SCA14 is associated with increased PKCγ kinase activity, mislocalization and aggregation.

Wong MMK, Hoekstra SD, Vowles J, Watson LM, Fuller G, Németh AH, Cowley SA, Ansorge O, Talbot K, Becker EBE.

Acta Neuropathol Commun. 2018 Sep 24;6(1):99. doi: 10.1186/s40478-018-0600-7.

14.

Frequency and signature of somatic variants in 1461 human brain exomes.

Wei W, Keogh MJ, Aryaman J, Golder Z, Kullar PJ, Wilson I, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Sarraj SA, Morris CM, Ansorge O, Jones NS, Ironside JW, Chinnery PF.

Genet Med. 2019 Apr;21(4):904-912. doi: 10.1038/s41436-018-0274-3. Epub 2018 Sep 14.

15.

Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.

Carter RLR, Talbot K, Hur WS, Meixner SC, Van Der Gugten JG, Holmes DT, Côté HCF, Kastrup CJ, Smith TW, Lee AYY, Pryzdial ELG.

J Thromb Haemost. 2018 Nov;16(11):2276-2288. doi: 10.1111/jth.14281. Epub 2018 Oct 9.

PMID:
30176116
16.

Amyotrophic lateral sclerosis: the complex path to precision medicine.

Talbot K, Feneberg E, Scaber J, Thompson AG, Turner MR.

J Neurol. 2018 Oct;265(10):2454-2462. doi: 10.1007/s00415-018-8983-8. Epub 2018 Jul 27.

17.

Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis.

Tu S, Menke RAL, Talbot K, Kiernan MC, Turner MR.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1250-1258. doi: 10.1136/jnnp-2018-318625. Epub 2018 Jul 26.

PMID:
30049750
18.

ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function.

de Majo M, Topp SD, Smith BN, Nishimura AL, Chen HJ, Gkazi AS, Miller J, Wong CH, Vance C, Baas F, Ten Asbroek ALMA, Kenna KP, Ticozzi N, Redondo AG, Esteban-Pérez J, Tiloca C, Verde F, Duga S, Morrison KE, Shaw PJ, Kirby J, Turner MR, Talbot K, Hardiman O, Glass JD, de Belleroche J, Gellera C, Ratti A, Al-Chalabi A, Brown RH, Silani V, Landers JE, Shaw CE.

Neurobiol Aging. 2018 Nov;71:266.e1-266.e10. doi: 10.1016/j.neurobiolaging.2018.06.015. Epub 2018 Jun 25.

19.

Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis.

Salter M, Corfield E, Ramadass A, Grand F, Green J, Westra J, Lim CR, Farrimond L, Feneberg E, Scaber J, Thompson A, Ossher L, Turner M, Talbot K, Cudkowicz M, Berry J, Hunter E, Akoulitchev A.

EBioMedicine. 2018 Jul;33:169-184. doi: 10.1016/j.ebiom.2018.06.015. Epub 2018 Jun 23.

20.

Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis.

Proudfoot M, van Ede F, Quinn A, Colclough GL, Wuu J, Talbot K, Benatar M, Woolrich MW, Nobre AC, Turner MR.

Clin Neurophysiol. 2018 Jul;129(7):1479-1489. doi: 10.1016/j.clinph.2018.03.019. Epub 2018 Apr 6.

PMID:
29678369
21.

Increased cerebral functional connectivity in ALS: A resting-state magnetoencephalography study.

Proudfoot M, Colclough GL, Quinn A, Wuu J, Talbot K, Benatar M, Nobre AC, Woolrich MW, Turner MR.

Neurology. 2018 Apr 17;90(16):e1418-e1424. doi: 10.1212/WNL.0000000000005333. Epub 2018 Mar 21.

22.

Insulin resistance and cognitive test performance in elderly adults: National health and nutrition examination survey (NHANES).

Sherzai AZ, Shaheen M, Yu JJ, Talbot K, Sherzai D.

J Neurol Sci. 2018 May 15;388:97-102. doi: 10.1016/j.jns.2017.11.031. Epub 2017 Nov 23.

PMID:
29627040
23.

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.

Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH.

Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.

24.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

25.

Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis.

Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, Ealing J, Hanemann CO, Harrower T, McDermott CJ, Majeed T, Pinto A, Talbot K, Williams T, Young CA; TONiC study group.

Acta Neurol Scand. 2018 Jul;138(1):47-54. doi: 10.1111/ane.12910. Epub 2018 Feb 21.

PMID:
29468643
26.

Towards a TDP-43-Based Biomarker for ALS and FTLD.

Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR.

Mol Neurobiol. 2018 Oct;55(10):7789-7801. doi: 10.1007/s12035-018-0947-6. Epub 2018 Feb 19. Review.

27.

Advances in therapy for spinal muscular atrophy: promises and challenges.

Groen EJN, Talbot K, Gillingwater TH.

Nat Rev Neurol. 2018 Apr;14(4):214-224. doi: 10.1038/nrneurol.2018.4. Epub 2018 Feb 9. Review.

PMID:
29422644
28.

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.

Benoy V, Van Helleputte L, Prior R, d'Ydewalle C, Haeck W, Geens N, Scheveneels W, Schevenels B, Cader MZ, Talbot K, Kozikowski AP, Vanden Berghe P, Van Damme P, Robberecht W, Van Den Bosch L.

Brain. 2018 Mar 1;141(3):673-687. doi: 10.1093/brain/awx375.

29.

Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains.

Keogh MJ, Wei W, Aryaman J, Wilson I, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Al Sarraj S, Morris CM, Ansorge O, Pickering-Brown S, Jones N, Ironside JW, Chinnery PF.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):813-816. doi: 10.1136/jnnp-2017-317234. Epub 2018 Jan 13.

30.

Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis.

Thompson AG, Gray E, Thézénas ML, Charles PD, Evetts S, Hu MT, Talbot K, Fischer R, Kessler BM, Turner MR.

Ann Neurol. 2018 Feb;83(2):258-268. doi: 10.1002/ana.25143. Epub 2018 Feb 9.

PMID:
29331073
31.

The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis.

Menke RAL, Proudfoot M, Talbot K, Turner MR.

Neuroimage Clin. 2017 Dec 18;17:953-961. doi: 10.1016/j.nicl.2017.12.025. eCollection 2018.

32.

Mapping Extracellular Matrix Proteins in Formalin-Fixed, Paraffin-Embedded Tissues by MALDI Imaging Mass Spectrometry.

Angel PM, Comte-Walters S, Ball LE, Talbot K, Mehta A, Brockbank KGM, Drake RR.

J Proteome Res. 2018 Jan 5;17(1):635-646. doi: 10.1021/acs.jproteome.7b00713. Epub 2017 Dec 11.

33.

Prospective memory in children with attention deficit hyperactivity disorder: a review.

Talbot KS, Müller U, Kerns KA.

Clin Neuropsychol. 2018 Jul;32(5):783-815. doi: 10.1080/13854046.2017.1393563. Epub 2017 Oct 24. Review.

PMID:
29065807
34.

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.

Wood MJA, Talbot K, Bowerman M.

Hum Mol Genet. 2017 Oct 1;26(R2):R151-R159. doi: 10.1093/hmg/ddx215. Review.

PMID:
28977438
35.

July 2017 ENCALS statement on edaravone.

Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Review. No abstract available.

36.

Fundus fluorescein angiography in Susac's syndrome.

Reynolds GL, Talbot K, Sharma SM.

Pract Neurol. 2017 Dec;17(6):472-473. doi: 10.1136/practneurol-2017-001727. Epub 2017 Aug 17. No abstract available.

PMID:
28819045
37.

Therapeutic strategies for spinal muscular atrophy: SMN and beyond.

Bowerman M, Becker CG, Yáñez-Muñoz RJ, Ning K, Wood MJA, Gillingwater TH, Talbot K; UK SMA Research Consortium.

Dis Model Mech. 2017 Aug 1;10(8):943-954. doi: 10.1242/dmm.030148. Review.

38.

The clinical landscape for SMA in a new therapeutic era.

Talbot K, Tizzano EF.

Gene Ther. 2017 Sep;24(9):529-533. doi: 10.1038/gt.2017.52. Epub 2017 Jul 23. Review.

39.

Genetic screening in sporadic ALS and FTD.

Turner MR, Al-Chalabi A, Chio A, Hardiman O, Kiernan MC, Rohrer JD, Rowe J, Seeley W, Talbot K.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1042-1044. doi: 10.1136/jnnp-2017-315995. Epub 2017 Jun 22.

40.

Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis.

Fabes J, Matthews L, Filippini N, Talbot K, Jenkinson M, Turner MR.

Acad Radiol. 2017 Oct;24(10):1187-1194. doi: 10.1016/j.acra.2017.04.008. Epub 2017 May 29.

41.

The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA.

Christie-Brown V, Mitchell J, Talbot K.

Gene Ther. 2017 Sep;24(9):544-546. doi: 10.1038/gt.2017.47. Epub 2017 May 31. Review.

PMID:
28561814
42.

Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.

Smith BN, Topp SD, Fallini C, Shibata H, Chen HJ, Troakes C, King A, Ticozzi N, Kenna KP, Soragia-Gkazi A, Miller JW, Sato A, Dias DM, Jeon M, Vance C, Wong CH, de Majo M, Kattuah W, Mitchell JC, Scotter EL, Parkin NW, Sapp PC, Nolan M, Nestor PJ, Simpson M, Weale M, Lek M, Baas F, Vianney de Jong JM, Ten Asbroek ALMA, Redondo AG, Esteban-Pérez J, Tiloca C, Verde F, Duga S, Leigh N, Pall H, Morrison KE, Al-Chalabi A, Shaw PJ, Kirby J, Turner MR, Talbot K, Hardiman O, Glass JD, De Belleroche J, Maki M, Moss SE, Miller C, Gellera C, Ratti A, Al-Sarraj S, Brown RH Jr, Silani V, Landers JE, Shaw CE.

Sci Transl Med. 2017 May 3;9(388). pii: eaad9157. doi: 10.1126/scitranslmed.aad9157.

43.

Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations.

Sleigh JN, Dawes JM, West SJ, Wei N, Spaulding EL, Gómez-Martín A, Zhang Q, Burgess RW, Cader MZ, Talbot K, Yang XL, Bennett DL, Schiavo G.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3324-E3333. doi: 10.1073/pnas.1614557114. Epub 2017 Mar 28.

44.

C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia.

Aoki Y, Manzano R, Lee Y, Dafinca R, Aoki M, Douglas AGL, Varela MA, Sathyaprakash C, Scaber J, Barbagallo P, Vader P, Mäger I, Ezzat K, Turner MR, Ito N, Gasco S, Ohbayashi N, El Andaloussi S, Takeda S, Fukuda M, Talbot K, Wood MJA.

Brain. 2017 Apr 1;140(4):887-897. doi: 10.1093/brain/awx024. Erratum in: Brain. 2018 May 1;141(5):e42.

PMID:
28334866
45.

AdVance male urethral sling: medium-term results in an Australian cohort.

Papachristos A, Mann S, Talbot K, Moon D.

ANZ J Surg. 2018 Mar;88(3):E178-E182. doi: 10.1111/ans.13890. Epub 2017 Feb 27.

PMID:
28239989
46.

ADCY5-related dyskinesia presenting as familial myoclonus-dystonia.

Douglas AG, Andreoletti G, Talbot K, Hammans SR, Singh J, Whitney A, Ennis S, Foulds NC.

Neurogenetics. 2017 Apr;18(2):111-117. doi: 10.1007/s10048-017-0510-z. Epub 2017 Feb 22.

47.

Erratum to: Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains.

Wei W, Keogh MJ, Wilson I, Coxhead J, Ryan S, Rollinson S, Griffin H, Kurzawa-Akanbi M, Santibanez-Koref M, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Al Sarraj S, Morris CM, Ansorge O, Pickering-Brown S, Ironside JW, Chinnery PF.

Acta Neuropathol Commun. 2017 Feb 22;5(1):17. doi: 10.1186/s40478-017-0419-7. No abstract available.

48.

Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains.

Wei W, Keogh MJ, Wilson I, Coxhead J, Ryan S, Rollinson S, Griffin H, Kurzawa-Akanbi M, Santibanez-Koref M, Talbot K, Turner MR, McKenzie CA, Troakes C, Attems J, Smith C, Al Sarraj S, Morris CM, Ansorge O, Pickering-Brown S, Ironside JW, Chinnery PF.

Acta Neuropathol Commun. 2017 Feb 2;5(1):13. doi: 10.1186/s40478-016-0404-6. Erratum in: Acta Neuropathol Commun. 2017 Feb 22;5(1):17.

49.

Whole-exome sequencing of 228 patients with sporadic Parkinson's disease.

Sandor C, Honti F, Haerty W, Szewczyk-Krolikowski K, Tomlinson P, Evetts S, Millin S, Keane T, McCarthy SA, Durbin R, Talbot K, Hu M, Webber C, Ponting CP, Wade-Martins R.

Sci Rep. 2017 Jan 24;7:41188. doi: 10.1038/srep41188.

50.

A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS.

Thompson AG, Blackwell V, Marsden R, Millard E, Lawson C, Nickol AH, East JE, Talbot K, Allan PJ, Turner MR.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):243-248. doi: 10.1080/21678421.2016.1274330. Epub 2017 Jan 19.

Supplemental Content

Loading ...
Support Center